ABC | Volume 111, Nº2, Agosto 2018

Artigo de Revisão Leite et al Aspirina e terapia hormonal no câncer de mama Arq Bras Cardiol. 2018; 111(2):205-212 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 42. Cheng R, Liu YJ, Cui JW, Yang M, Liu XL, Li P, et al. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast câncer cells. Oncotarget. 2017;8(18):30252-64. 43. Duvernoy CS, Yeo AA, WongM, Cox DA, KimHM. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial. J Womens Health (Larchmt). 2010;19(8):1459-65. 44. Holmes MD, ChenWY, Li L, Hertzmark E, Spiegelman D, Hankinson SE, et al. Aspirinintakeandsurvivalafterbreastcancer.JClinOncol.2010;28(9):1467-72. 45. Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM, et al. Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden. BMCCancer. 2014 Jun 2;14:391-2. 46. Yang YS, Kornelius E, Chiou JY, Lai YR, Lo SC, Peng CH, et al. Low-dose aspirin reducesbreastcancerriskinwomenwithdiabetes:aNationwideRetrospective Cohort Study in Taiwan. JWomens Health (Larchmt). 2017;26(12):1278-84. 47. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111(3):623-7. 48. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1586-91.  49. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403-15. 50. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518-27. 51. Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):239-42. 52. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet. 2011;377(9759):31-41. 53. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti- inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71-3.  54. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501-7. 55. Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, et al. Aspirin in the treatment of cancer: reductions inmetastatic spread and inmortality: a systematic review and meta-analyses of published studies. PLoS One. 2016;11(4):e0152402. 56. ChenWY, Holmes MD. Role of aspirin in breast câncer survival. Curr Oncol Rep. 2017;19(7):48. 212